{"disease":{"id":"oligodendroglioma-idh-mutant-and-1p-19q-codeleted","name":"oligodendroglioma idh mutant and 1p 19q codeleted"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05303519","title":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT06625047","title":"Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}